​

Natera (NTRA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NTRA Stock Forecast

Natera (NTRA) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $202.50, with a high of $268.00 and a low of $172.00. This represents a 5.35% increase from the last price of $192.22.

$50 $100 $150 $200 $250 $300 High: $268 Avg: $202.5 Low: $172 Last Closed Price: $192.22

NTRA Stock Rating

Natera stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 25 Buy (96.15%), 1 Hold (3.85%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 1 25 Strong Sell Sell Hold Buy Strong Buy

NTRA Price Target Upside V Benchmarks

TypeNameUpside
StockNatera5.35%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks6.76%

Price Target Trends

1M3M12M
# Anlaysts148
Avg Price Target$172.00$202.50$187.13
Last Closing Price$192.22$192.22$192.22
Upside/Downside-10.52%5.35%-2.65%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 255131-120
Sep, 25613--120
Aug, 25613--120
Jul, 25712--120
Jun, 25812--121
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2025Navann TyBNP Paribas$172.00$192.36-10.58%-10.52%
Sep 22, 2025Brandon CouillardWells Fargo$175.00$181.11-3.37%-8.96%
Sep 02, 2025Conor McNamaraRBC Capital$268.00$169.3458.26%39.42%
Aug 10, 2025Patrick WoodMorgan Stanley$195.00$151.9528.33%1.45%
Feb 28, 2025Canaccord Genuity$195.00$155.5925.33%1.45%
Nov 13, 2024Tycho PetersonJefferies$182.00$114.5758.85%-5.32%
Nov 13, 2024Catherine Ramsey SchulteRobert W. Baird$160.00$114.5739.65%-16.76%
Oct 29, 2024Kyle MiksonCanaccord Genuity$150.00$120.7124.26%-21.96%
Sep 13, 2024Dave WestenbergPiper Sandler$150.00$125.1219.88%-21.96%
Aug 27, 2024Kyle MiksonCanaccord Genuity$145.00$118.1122.77%-24.57%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 27, 2025Exane BNP ParibasNeutralupgrade
Oct 23, 2025BTIGBuyBuyhold
Sep 02, 2025RBC CapitalOutperformOutperformhold
Aug 11, 2025Piper SandlerOverweightOverweighthold
Aug 10, 2025Morgan StanleyOverweightOverweighthold
Aug 08, 2025Cowen & Co.BuyBuyhold
Aug 08, 2025BarclaysOverweightOverweighthold
May 15, 2025Piper SandlerOverweightOverweighthold
Mar 04, 2025Piper SandlerOverweightOverweighthold
Feb 28, 2025BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.84$-5.21$-5.57$-3.78$-1.53----
Avg Forecast$-2.54$-5.02$-5.60$-3.96$-1.50$-1.20$0.02$0.98$1.46
High Forecast$-2.48$-4.90$-5.26$-3.87$-1.22$-0.79$0.37$2.21$1.53
Low Forecast$-2.69$-5.32$-5.85$-4.05$-1.61$-1.51$-0.15$0.18$1.33
Surprise %11.81%3.78%-0.54%-4.55%2.00%----

Revenue Forecast

$0 $600M $1B $2B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$391.00M$625.49M$820.22M$1.08B$1.70B----
Avg Forecast$385.24M$621.43M$819.43M$1.07B$1.65B$1.82B$2.14B$2.46B$2.68B
High Forecast$403.22M$650.44M$846.85M$1.09B$1.66B$1.88B$2.15B$2.46B$2.79B
Low Forecast$378.23M$610.12M$780.38M$1.06B$1.64B$1.78B$2.14B$2.45B$2.50B
Surprise %1.50%0.65%0.10%1.17%2.72%----

Net Income Forecast

$-600M $-420M $-240M $-60M $120M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-229.74M$-471.72M$-547.80M$-434.80M$-190.43M----
Avg Forecast$-182.75M$-398.29M$-395.34M$-499.34M$-162.83M$-145.21M$33.61M$168.67M$167.89M
High Forecast$-146.20M$-318.63M$-316.27M$-399.47M$-140.20M$-90.38M$42.22M$253.93M$176.39M
Low Forecast$-219.30M$-477.94M$-474.40M$-599.21M$-185.46M$-173.31M$-17.72M$20.83M$152.77M
Surprise %25.71%18.44%38.57%-12.93%16.95%----

NTRA Forecast FAQ

Is Natera stock a buy?

Natera stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 25 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Natera is a favorable investment for most analysts.

What is Natera's price target?

Natera's price target, set by 26 Wall Street analysts, averages $202.5 over the next 12 months. The price target range spans from $172 at the low end to $268 at the high end, suggesting a potential 5.35% change from the previous closing price of $192.22.

How does Natera stock forecast compare to its benchmarks?

Natera's stock forecast shows a 5.35% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (6.76%).

What is the breakdown of analyst ratings for Natera over the past three months?

  • October 2025: 25.00% Strong Buy, 65.00% Buy, 5.00% Hold, 0% Sell, 5.00% Strong Sell.
  • September 2025: 30.00% Strong Buy, 65.00% Buy, 0% Hold, 0% Sell, 5.00% Strong Sell.
  • August 2025: 30.00% Strong Buy, 65.00% Buy, 0% Hold, 0% Sell, 5.00% Strong Sell.

What is Natera’s EPS forecast?

Natera's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.2, marking a -21.57% decrease from the reported $-1.53 in 2024. Estimates for the following years are $0.02 in 2026, $0.98 in 2027, and $1.46 in 2028.

What is Natera’s revenue forecast?

Natera's average annual revenue forecast for its fiscal year ending in December 2025 is $1.82B, reflecting a 7.18% increase from the reported $1.7B in 2024. The forecast for 2026 is $2.14B, followed by $2.46B for 2027, and $2.68B for 2028.

What is Natera’s net income forecast?

Natera's net income forecast for the fiscal year ending in December 2025 stands at $-145M, representing a -23.74% decrease from the reported $-190M in 2024. Projections indicate $33.61M in 2026, $168.67M in 2027, and $167.89M in 2028.